[HTML] nih.gov

PD-L1 and HLA class I antigen expression and clinical course of the disease in intrahepatic cholangiocarcinoma

F Sabbatino, V Villani, JH Yearley, V Deshpande… - Clinical Cancer …, 2016 - AACR
Purpose: More effective therapy is needed for intrahepatic cholangiocarcinoma (ICC). The
encouraging clinical results obtained with checkpoint molecule-specific monoclonal …
被引用次数：212 相关文章 所有 7 个版本
[PDF] springer.com

HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1

CY Jing, YP Fu, Y Yi, MX Zhang, SS Zheng… - … for Immunotherapy of …, 2019 - Springer
Background Intrahepatic cholangiocarcinoma (ICC) is a highly mortal malignancy with
limited therapeutic options. Immunotherapies targeting PD-1/PD-L1 pathway represent a …
被引用次数：111 相关文章 所有 13 个版本
[HTML] nih.gov

[HTML][HTML] PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma

J Fontugne, J Augustin, A Pujals, P Compagnon… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Cholangiocarcinoma is an aggressive biliary neoplasm lacking effective therapeutic agents.
Immunotherapies targeting the PD-L1/PD-1 immune checkpoint have shown encouraging …
被引用次数：173 相关文章 所有 8 个版本
[PDF] springer.com

PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome

L Tian, J Ma, L Ma, B Zheng, L Liu, D Song… - World journal of surgical …, 2020 - Springer
Objective Immunotherapy targeting the programmed cell death protein-1 (PD-
1)/programmed cell death protein ligand 1 (PD-L1) pathway has been observed to be …
被引用次数：41 相关文章 所有 12 个版本
[HTML] nih.gov

[HTML][HTML] Distinct PD-L1/PD1 profiles and clinical implications in intrahepatic cholangiocarcinoma patients with different risk factors

JC Lu, HY Zeng, QM Sun, QN Meng, XY Huang… - Theranostics, 2019 - ncbi.nlm.nih.gov
Abstract Rationale: PD1/PD-L1 immune checkpoint inhibitors have shown promising results
for several malignancies. However, PD1/PD-L1 signaling and its therapeutic significance …
被引用次数：78 相关文章 所有 8 个版本

Prognostic impact of CD8+ T cell distribution and its association with the HLA class I expression in intrahepatic cholangiocarcinoma

Y Asahi, KC Hatanaka, Y Hatanaka, T Kamiyama… - Surgery Today, 2020 - Springer
Purpose A lack of effective systemic therapy is one reason for the poor prognosis of
intrahepatic cholangiocarcinoma. Newly developed immune checkpoint inhibitors function …
被引用次数：45 相关文章 所有 5 个版本

PD‐L1 expression in extrahepatic cholangiocarcinoma

D Walter, E Herrmann, AA Schnitzbauer… - …, 2017 - Wiley Online Library
Aims To investigate the expression of the programmed cell death 1 (PD‐1) receptor–
programmed cell death ligand 1 (PD‐L1) pathway and the clinicopathological characteristics …
被引用次数：74 相关文章 所有 5 个版本
[PDF] springer.com

Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients

M Deng, SH Li, X Fu, XP Yan, J Chen, YD Qiu… - Cancer cell …, 2021 - Springer
Background Programmed death-ligand 1 (PD-L1) seems to be associated with the immune
escape of tumors, and immunotherapy may be a favorable treatment for PD-L1-positive …
被引用次数：33 相关文章 所有 13 个版本

Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules

G Zhou, D Sprengers, S Mancham, R Erkens… - Journal of …, 2019 - Elsevier
Background & Aims Cholangiocarcinoma is an aggressive hepatobiliary malignancy
originating from biliary tract epithelium. Whether cholangiocarcinoma is responsive to …
被引用次数：116 相关文章 所有 8 个版本
[PDF] tandfonline.com

Programmed death ligand 1 expression in human intrahepatic cholangiocarcinoma and its association with prognosis and CD8+ T-cell immune responses

Y Zhu, XY Wang, Y Zhang, D Xu, J Dong… - Cancer management …, 2018 - Taylor & Francis
Background Agents targeting the programmed death ligand 1 (PD-L1)/programmed death
receptor 1 immune checkpoint exhibited promising clinical outcomes in a variety of …
被引用次数：54 相关文章 所有 9 个版本